TY - JOUR
T1 - Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
AU - Tartaglia, Marco
AU - Mehler, Ernest L.
AU - Goldberg, Rosalie
AU - Zampino, Giuseppe
AU - Brunner, Han G.
AU - Kremer, Hannie
AU - Van Der Burgt, Ineke
AU - Crosby, Andrew H.
AU - Ion, Andra
AU - Jeffery, Steve
AU - Kalidas, Kamini
AU - Patton, Michael A.
AU - Kucherlapati, Raju S.
AU - Gelb, Bruce D.
PY - 2001
Y1 - 2001
N2 - Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy). Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diatheses also are frequently associated with this disease. This syndrome is relatively common, with an estimated incidence of 1 in 1,000-2,500 live births. It has been mapped to a 5-cM region (NS1) [corrected] on chromosome 12q24.1, and genetic heterogeneity has also been documented. Here we show that missense mutations in PTPN11 (MIM 176876)-a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homology 2 (SH2) domains-cause Noonan syndrome and account for more than 50% of the cases that we examined. All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations. An energetics-based structural analysis of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equilibrium favoring the active conformation. This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.
AB - Noonan syndrome (MIM 163950) is an autosomal dominant disorder characterized by dysmorphic facial features, proportionate short stature and heart disease (most commonly pulmonic stenosis and hypertrophic cardiomyopathy). Webbed neck, chest deformity, cryptorchidism, mental retardation and bleeding diatheses also are frequently associated with this disease. This syndrome is relatively common, with an estimated incidence of 1 in 1,000-2,500 live births. It has been mapped to a 5-cM region (NS1) [corrected] on chromosome 12q24.1, and genetic heterogeneity has also been documented. Here we show that missense mutations in PTPN11 (MIM 176876)-a gene encoding the nonreceptor protein tyrosine phosphatase SHP-2, which contains two Src homology 2 (SH2) domains-cause Noonan syndrome and account for more than 50% of the cases that we examined. All PTPN11 missense mutations cluster in interacting portions of the amino N-SH2 domain and the phosphotyrosine phosphatase domains, which are involved in switching the protein between its inactive and active conformations. An energetics-based structural analysis of two N-SH2 mutants indicates that in these mutants there may be a significant shift of the equilibrium favoring the active conformation. This implies that they are gain-of-function changes and that the pathogenesis of Noonan syndrome arises from excessive SHP-2 activity.
KW - Chromosomes, Human, Pair 12
KW - Genetic Heterogeneity
KW - Humans
KW - Intracellular Signaling Peptides and Proteins
KW - Models, Molecular
KW - Molecular Sequence Data
KW - Mutation, Missense
KW - Noonan Syndrome
KW - Protein Conformation
KW - Protein Tyrosine Phosphatase, Non-Receptor Type 11
KW - Protein Tyrosine Phosphatase, Non-Receptor Type 6
KW - Protein Tyrosine Phosphatases
KW - Chromosomes, Human, Pair 12
KW - Genetic Heterogeneity
KW - Humans
KW - Intracellular Signaling Peptides and Proteins
KW - Models, Molecular
KW - Molecular Sequence Data
KW - Mutation, Missense
KW - Noonan Syndrome
KW - Protein Conformation
KW - Protein Tyrosine Phosphatase, Non-Receptor Type 11
KW - Protein Tyrosine Phosphatase, Non-Receptor Type 6
KW - Protein Tyrosine Phosphatases
UR - http://hdl.handle.net/10807/36995
U2 - 10.1038/ng772
DO - 10.1038/ng772
M3 - Article
SN - 1061-4036
VL - 29
SP - 465
EP - 468
JO - Nature Genetics
JF - Nature Genetics
ER -